DE2646186A1 - Antihypertonika - Google Patents

Antihypertonika

Info

Publication number
DE2646186A1
DE2646186A1 DE19762646186 DE2646186A DE2646186A1 DE 2646186 A1 DE2646186 A1 DE 2646186A1 DE 19762646186 DE19762646186 DE 19762646186 DE 2646186 A DE2646186 A DE 2646186A DE 2646186 A1 DE2646186 A1 DE 2646186A1
Authority
DE
Germany
Prior art keywords
amino
compound
dimethoxyquinazoline
tetrahydropyran
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19762646186
Other languages
German (de)
English (en)
Other versions
DE2646186C2 (US20030204162A1-20031030-M00001.png
Inventor
Daniel Ambrose Dunnigan
Peter Hadley Jones
Jaroslav Kyncl
Martin Winn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24492453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE2646186(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE2646186A1 publication Critical patent/DE2646186A1/de
Application granted granted Critical
Publication of DE2646186C2 publication Critical patent/DE2646186C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19762646186 1975-10-14 1976-10-13 Antihypertonika Granted DE2646186A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/621,980 US4026894A (en) 1975-10-14 1975-10-14 Antihypertensive agents

Publications (2)

Publication Number Publication Date
DE2646186A1 true DE2646186A1 (de) 1977-04-28
DE2646186C2 DE2646186C2 (US20030204162A1-20031030-M00001.png) 1987-10-29

Family

ID=24492453

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762646186 Granted DE2646186A1 (de) 1975-10-14 1976-10-13 Antihypertonika

Country Status (10)

Country Link
US (2) US4026894A (US20030204162A1-20031030-M00001.png)
JP (1) JPS5248678A (US20030204162A1-20031030-M00001.png)
AU (1) AU498925B2 (US20030204162A1-20031030-M00001.png)
CA (1) CA1057754A (US20030204162A1-20031030-M00001.png)
CH (1) CH602712A5 (US20030204162A1-20031030-M00001.png)
DE (1) DE2646186A1 (US20030204162A1-20031030-M00001.png)
FR (1) FR2327787A1 (US20030204162A1-20031030-M00001.png)
GB (1) GB1517403A (US20030204162A1-20031030-M00001.png)
MX (1) MX3620E (US20030204162A1-20031030-M00001.png)
SE (2) SE422685B (US20030204162A1-20031030-M00001.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2831112A1 (de) * 1977-08-04 1979-02-15 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-chinazolinyl)-4-(2-tetrahydrofuroyl)-piperazin-hydrochloriddihydrat
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4279910A (en) * 1979-04-25 1981-07-21 Pfizer Inc. Quinazoline therapeutic agents
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
EP0188094A2 (en) * 1984-12-14 1986-07-23 Mitsui Petrochemical Industries, Ltd. Quinazoline derivatives and antihypertensive preparations containing same as effective components
AT398075B (de) * 1989-04-21 1994-09-26 Egyt Gyogyszervegyeszeti Gyar Verfahren zur herstellung von chinazolinderivaten

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0022481A1 (en) * 1979-06-21 1981-01-21 Mitsubishi Yuka Pharmaceutical Co., Ltd. 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions
HU180708B (en) * 1979-10-11 1983-04-29 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 1,2,4-oxadiazine derivatives
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
DE3683760D1 (de) * 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
JPH03286800A (ja) * 1990-04-03 1991-12-17 Gunze Ltd 衣類の折畳み装置
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
CA2232138A1 (en) * 1995-09-29 1997-04-03 William C. Lumma Alpha 1b adrenergic receptor antagonists
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
CA2173408C (en) * 1996-04-03 2001-09-04 K.S. Keshava Murthy Process for the manufacture of intermediates suitable to make doxazosin,terazosin, prazosin, tiodazosin and related antihypertensive medicines
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
EP1118322A4 (en) 1998-09-30 2004-10-20 Takeda Chemical Industries Ltd MEDICINES FOR IMPROVING BUBBLE EMPTYING STRENGTH
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2679030A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary track symptoms
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
KR20060126448A (ko) 2003-09-12 2006-12-07 알러간, 인코포레이티드 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
CA2500676A1 (en) * 2005-03-11 2006-09-11 Apotex Pharmachem Inc. Preparation of acid addition salts of amine bases by solid phase-gas phase reactions
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
US20070161791A1 (en) * 2006-01-09 2007-07-12 Narsimha Reddy Penthala Process for the preparation of terazosin hydrocloride dihydrate
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
US8389531B2 (en) * 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
CN103739596A (zh) * 2013-12-10 2014-04-23 刘磊 用于心脑血管疾病的喹唑啉衍生物
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2120495A1 (de) * 1970-05-21 1971-12-02 Pfizer Inc., New York, N.Y. (V.St.A.) Neue Trialkoxychinazolin-Verbindungen und Verfahren zu ihrer Herstellung
DE2354389A1 (de) * 1972-10-30 1974-05-09 Eisai Co Ltd Chinazolinverbindungen und verfahren zu ihrer herstellung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2120495A1 (de) * 1970-05-21 1971-12-02 Pfizer Inc., New York, N.Y. (V.St.A.) Neue Trialkoxychinazolin-Verbindungen und Verfahren zu ihrer Herstellung
DE2354389A1 (de) * 1972-10-30 1974-05-09 Eisai Co Ltd Chinazolinverbindungen und verfahren zu ihrer herstellung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Brit. Med. Journal 1975, S. 727-728 *
The Lancet 1975, S. 1095 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2831112A1 (de) * 1977-08-04 1979-02-15 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-chinazolinyl)-4-(2-tetrahydrofuroyl)-piperazin-hydrochloriddihydrat
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4279910A (en) * 1979-04-25 1981-07-21 Pfizer Inc. Quinazoline therapeutic agents
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
EP0188094A2 (en) * 1984-12-14 1986-07-23 Mitsui Petrochemical Industries, Ltd. Quinazoline derivatives and antihypertensive preparations containing same as effective components
EP0188094A3 (en) * 1984-12-14 1987-12-23 Mitsui Petrochemical Industries, Ltd. Quinazoline derivatives and antihypertensive preparations containing same as effective components
AT398075B (de) * 1989-04-21 1994-09-26 Egyt Gyogyszervegyeszeti Gyar Verfahren zur herstellung von chinazolinderivaten

Also Published As

Publication number Publication date
FR2327787A1 (fr) 1977-05-13
DE2646186C2 (US20030204162A1-20031030-M00001.png) 1987-10-29
FR2327787B1 (US20030204162A1-20031030-M00001.png) 1980-10-10
GB1517403A (en) 1978-07-12
CH602712A5 (US20030204162A1-20031030-M00001.png) 1978-07-31
SE7611379L (sv) 1977-04-15
CA1057754A (en) 1979-07-03
JPS5248678A (en) 1977-04-18
JPS5543474B2 (US20030204162A1-20031030-M00001.png) 1980-11-06
SE431208B (sv) 1984-01-23
US4112097A (en) 1978-09-05
SE422685B (sv) 1982-03-22
AU498925B2 (en) 1979-03-29
US4026894A (en) 1977-05-31
SE8008533L (sv) 1980-12-04
AU1655776A (en) 1978-02-09
MX3620E (es) 1981-04-02

Similar Documents

Publication Publication Date Title
DE2646186C2 (US20030204162A1-20031030-M00001.png)
DE2858042C2 (de) Rechtsdrehendes Isomer eines asymmetrischen Spirohydantoins sowie der Basensalze hiervon und ihre Verwendung
DE2734070C2 (de) Aminoalkylfuranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AT402894B (de) Kombination von angiotensin-converting-enzyme- hemmern mit calciumantagonisten sowie ein erzeugnis, das diese enthält, zur anwendung bei der behandlung des bluthochdrucks
DE3709621A1 (de) Therapeutisches mittel
DE2043933B2 (de) N-(beta-naphthylaminomethyl)-aminocarbonsaeuren sowie diese enthaltende arzneimittel
CH641159A5 (de) Verfahren zur herstellung von neuen guanidinderivaten.
DE2720545C3 (de) Derivate des 2,4-Diamino-6,7-dimethoxychinazolins, ihre Herstellung und pharmazeutische Mittel
DE1470088A1 (de) Verfahren zur Herstellung von in 6-Stellung substituierten 3-Aminopyrazinoylguanidinen
DE2522218C3 (de) Zusammensetzung für die Human- oder Veterinärmedizin, Methylaminderivate und Verfahren zu deren Herstellung
DE1915230B2 (de) Hydroxyphenylalkylaminderivate, verfahren zu deren herstellung und arzneimittel auf deren basis
DE2428680C2 (de) 1-(2',4',6'-Trihydroxyphenyl)-propandion-(1,2)-Verbindungen, Verfahren zu deren Herstellung und Arzneimittel, die diese Verbindungen enthalten
DE2414345C3 (de) (Z)-(3-Methyl-4-oxo-5-piperidinothiazolidin-2-yIiden)-esssigsäure und Verfahren zur Herstellung von Thiazolidinessigsäure-Derivaten
DE1768445C (de) N substituierte beta Oxybutyramid semisuccinate, deren Salze und ihre Her stellung
DE1443386C3 (de) Verfahren zur Herstellung von 3-Cyanguanidinderivaten
DE1795003C3 (de) 4H-13-Benzoxazin-2-on-3-acetohydroxamsäure, Verfahren zu deren Herstellung und Arzneimittel
AT371101B (de) Verfahren zur herstellung neuer optisch aktiver phenethanolamine und der pharmazeutisch unbedenklichen salze hiervon
DE1793590C3 (de) N-Cyclopropyl-N-propargyl- 1-aminoindan, dessen Salze und Arzneimittel auf dieser Grundlage. Ausscheidung aus': 1443403
DE2335437B2 (de) N-d-Indanyl-methyl)-2,6-dimethylpiperidin, seine Säureadditionssalze und ein diese Verbindung enthaltendes pharmazeutisches Mittel
DE1793190A1 (de) Verfahren zur Herstellung von 1-Amino-Adamantanen
CH645372A5 (de) 5-(2-((2,3-dihydro-1,4-benzodioxan-2-ylmethyl)amino)-1-hydroxyethyl)-2-hydroxybenzoesaeure-derivate sowie verfahren zu deren herstellung.
DE3104884A1 (de) Pharmazeutische zubereitung
DE2354999C3 (de) Dibenzo(b,f)azepin-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE2065966A1 (de) N-sulfonyl-aminocarbonsaeuren, sowie diese enthaltende arzneimittel
AT213395B (de) Verfahren zur Herstellung des neuen β-Hydroxybuttersäure-cyclohexylamids

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: ABITZ, W., DIPL.-ING.DR.-ING. MORF, D., DR., PAT.-

D2 Grant after examination
8364 No opposition during term of opposition